SCHEMBL17023903

SCHEMBL17023903

c1ccc(-c2nc(-c3ccccc3-c3nc(-c4ccccc4)n4ccccc34)c3ccccn23)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.55
KMT2A Q03164 4/20 0.55
GAA P10253 3/20 0.55
MEN1 O00255 3/20 0.55
POLB P06746 2/20 0.55
NPSR1 Q6W5P4 1/20 0.55
L3MBTL1 Q9Y468 2/20 0.50
MAPK1 P28482 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
HIF1A Q16665 7/20 0.49
EPAS1 Q99814 7/20 0.49
ALDH1A1 P00352 8/20 0.45
KDM4E B2RXH2 6/20 0.45
MAPT P10636 5/20 0.44
CHEK1 O14757 1/20 0.43
LIMK1 P53667 1/20 0.43
MAPK14 Q16539 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
LMNA P02545 1/20 0.42
NPC1 O15118 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13325874 0.89 KMT2A (0.67) HPGDKMT2AGAAMEN1POLB
SCHEMBL22426413 0.89 KMT2A (0.49) HPGDKMT2AGAAMEN1POLB
SCHEMBL17023890 0.87 MEN1 (0.65) HPGDKMT2AGAAMEN1POLB
SCHEMBL17023874 0.86 KMT2A (0.59) HPGDKMT2AGAAMEN1POLB
SCHEMBL17023878 0.86 KMT2A (0.55) HPGDKMT2AGAAMEN1POLB
SCHEMBL17023891 0.84 KMT2A (0.57) HPGDKMT2AGAAMEN1POLB
SCHEMBL17023893 0.81 HIF1A (0.59) HPGDKMT2AGAAMEN1POLB
SCHEMBL17023886 0.81 KMT2A (0.51) HPGDKMT2AGAAMEN1POLB
SCHEMBL17023871 0.81 KMT2A (0.51) HPGDKMT2AGAAMEN1POLB
SCHEMBL13325876 0.81 HIF1A (0.59) HPGDKMT2AGAAMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10847726-B2 Imidizo derivatives THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) 2020-11-24 US disclosed
US-20190131538-A1 IMIDIZO DERIVATIVES THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY 2019-05-02 US disclosed
US-20150243896-A1 IMIDAZO DERIVATIVES ARMY, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE 2015-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190131538-A1 IMIDIZO DERIVATIVES IKZF1, IKZF3, IKZF2 HPGD 2227/4885KMT2A 1089/4885GAA 3973/4885
US-10847726-B2 Imidizo derivatives IKZF1, IKZF3, IKZF2 HPGD 2227/4885KMT2A 1089/4885GAA 3973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.